Gilead and Novo Nordisk have announced their drug combinations for the fatty liver disease known as NASH checked out in a mid-stage proof-of-concept study. The companies said the trial met its primary ...
A regimen based on Jazz Pharma and PharmaMar's Zepzelca and Roche's Tecentriq has been approved in the US as a maintenance therapy for extensive-stage small-cell lung cancer (ES-SCLC). The approval ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback